Search results
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 6 days agoThe firm's stance comes after Pfizer (NYSE:PFE) announced its phase 3 trial for a gene therapy...
Pfizer's DMD gene therapy falls short in phase 3 trial
Becker’s Hospital Review· 6 days agoPfizer's gene therapy candidate for Duchenne muscular dystrophy failed to meet its primary endpoint in a phase 3 trial, the company said June 12. The study ...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 6 days ago, opens new tab said on Wednesday its experimental gene therapy for Duchenne muscular dystrophy...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 5 days agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Health Care Flat on Mixed Drug Developments
Market Watch· 5 days agoPublished: June 13, 2024 at 5:14 p.m. ETShareResizeHealth-care companies were more or less flat amid mixed drug developments.Rare-disease drug maker Sarepta Therapeutics rose sharply after analysts ...
Kyra Sedgwick on Finding Freedom in Directing, Plans to Make a Horror Movie With Her Family, and...
Variety via Yahoo News· 6 days ago“Don’t worry,” Kyra Sedgwick assures me as she assembles a salad. “I washed my hands.” We’re in her...
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at Piper Sandler
ETF DAILY NEWS· 5 days agoPiper Sandler started coverage on shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) in a research note published on Thursday, MarketBeat reports. The firm issued an overweight rating and ...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 6 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
A controversial gene therapy from a Cambridge biotech could get FDA approval this week - Boston...
The Business Journals· 2 days agoThe treatment, known as Elevidys, is made by Sarepta Therapeutics to treat Duchenne muscular ...
PepGen (NASDAQ:PEPG) Reaches New 1-Year High at $18.38
ETF DAILY NEWS· 5 days agoShares of PepGen Inc. (NASDAQ:PEPG – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $18.38 and last traded at $18.11, with a volume of ...
